http://www.salviabioelectronics.com/

Salvia BioElectronics, High Tech Campus 37, Eindhoven (2026)

23/04/2026

Why Migraine is Underdiagnosed
Migraine is the #2 cause of disability worldwide, yet it is still widely misdiagnosed and undertreated. Why?
▪️ Misconceptions (“it’s just a headache”)
▪️ Symptoms vary a lot
▪️ No simple diagnostic test
▪️ Recognition gaps in primary care and specialist settings

Migraine is often normalized by the people living with it, especially when it runs in families, which can make symptoms less likely to be reported as a problem.
In a transcontinental cohort, only 28% of primary care practitioners and 35% of specialist-trained physicians correctly diagnosed migraine, underscoring how variable the condition can be and how important it is for patients to describe the impact clearly.

This leaves millions untreated or undertreated.
At Salvia, we believe innovation must address these systemic challenges. Our mission: empower people with migraine to reclaim their lives.

21/03/2026

Most people have never heard of cluster headache. For those living with it, that invisibility is part of the burden.

Cluster headache is a severe neurological disorder that causes excruciating, one-sided pain behind the eye. Attacks can occur up to eight times per day, in clusters of one to two months, followed by periods of remission. For people with chronic cluster headache, those remissions are absent or last less than three months.

It affects 1 in 1,000 people. Unlike migraine, which predominantly affects women, cluster headache is more common in men. Genetics play a role in who is affected and how severely.

Today is Cluster Headache Awareness Day. A moment to make the invisible visible.

Today, Beat the Beast, Tacsweb and Hoofdpijnnet are bringing together patients, caregivers and clinicians in Nijmegen, the Netherlands, for a day of medical updates, peer connection and practical support. Salvia BioElectronics supported this event.

We stand with everyone affected by cluster headache. More awareness. More research. More urgency.

𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦.

17/03/2026

As Senior Usability Engineer at Salvia BioElectronics, Aurélie Debeyre plays a key role in ensuring the company’s novel neuromodulation therapy for people with migraine is designed with patients in mind. Her work connects research insights with the perspectives of healthcare professionals and Salvia’s engineering and development teams.

Originally from Lille, France, Aurélie joined Salvia last May after several years in Utrecht working for an American company. There, she collaborated with international teams and traveled regularly across the United States, visiting cities such as Chicago, Boston and Denver.

Early in her career as a consultant, Aurélie worked with large multidisciplinary teams at major companies developing a wide range of medical technologies, from complex surgical robots to injectable devices. Over time, she discovered she was most motivated by the opportunity to focus deeply on a single product and follow its development closely.

“When I saw the position at Salvia on LinkedIn, I was not really looking for a job. I was happy in my company,” Aurélie says. “But this position came at exactly the right moment for me.”

As Salvia’s Senior Usability Engineer, Aurélie focuses on how complex medical technology will actually be used in real-world healthcare environments. A product “is going to be used by someone at the end of the day, and my role is to bring everything I observe about the users and environment in which the product will be used.”

“What I really liked during the interview process is that Salvia always had the user in mind,” she says. “Patients are always part of the conversation, and the team works closely with physicians to make sure the product is safe and fits what people really need.”

On the personal side, Aurélie describes herself as reserved but not shy. Music and live performances are a big passion. She has traveled to see productions and concerts across Europe and the United States, including Sting’s The Last Ship in Amsterdam, and Oasis in Chicago.

“I don’t want to have any regrets, right?”

13/03/2026

What if your technical skills could support the development of implantable technology for migraine?

JOB | Equipment & Tooling Technician

At Salvia BioElectronics, we’re looking for an Equipment & Tooling Technician (Medical Devices) to join our team in Eindhoven.

You’ll work hands-on with advanced equipment in a cleanroom environment, supporting engineers in setting up, calibrating, maintaining, and improving production tools. Working closely with Operations, R&D, and Quality, you’ll play a key role in keeping our manufacturing processes running reliably and act as first-line support for equipment-related issues.

We are on a mission to empower people with migraine to reclaim their lives, developing a novel neuromodulation therapy currently being evaluated in clinical studies.

Why join us?
• Work on innovative implantable medical technology
• Collaborate with multidisciplinary teams
• Be part of a growing medtech company at High Tech Campus Eindhoven

Interested? Apply or share with someone who might be a great fit: https://www.salviabioelectronics.com/jobs/equipment-tooling-technician-2276564

12/03/2026

LSI USA ’26 is just around the corner.

Our CEO & Founder Hubert Martens and CFO Jeroen Siemes will attend LSI USA ’26 on behalf of Salvia BioElectronics, a clinical-stage company developing a novel neuromodulation therapy for people with migraine.

They look forward to connecting with investors, strategics and fellow innovators in and .

Interested in meeting at ? Feel free to reach out to schedule a conversation.

08/03/2026

Today, on International Women’s Day, we recognize the disproportionate burden that migraine places on women.

Chronic migraine is one of the most severe and disabling neurological disorders, and around 80% of people living with chronic migraine are women.

This reality is a powerful motivator for our work at Salvia BioElectronics. Every day we dedicate ourselves to developing a novel neuromodulation therapy for people affected by this debilitating condition.

Today we also recognize the incredible women in our team, who represent more than 40% of Salvia BioElectronics and play a vital role in advancing our science, technology, and mission. 🙏

Together, we remain committed to empowering people with migraine to reclaim their lives.

03/03/2026

𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐚 𝐧𝐨𝐯𝐞𝐥 𝐧𝐞𝐮𝐫𝐨𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐦𝐢𝐠𝐫𝐚𝐢𝐧𝐞

Today, Salvia BioElectronics celebrates 9 years.

Salvia was born from a strong personal drive combined with a clear and urgent medical need.

Chronic migraine is not “just a headache.”
It is a debilitating neurological condition that forces people out of their social lives, their work, and the life they want to live.

Nine years ago, our three founders turned that urgency into action. What began as a bold vision has grown into a multidisciplinary team of more than 60 scientists, engineers, and innovators, all driven by the same mission to empower people with migraine to reclaim their lives.

Today, we are advancing our investigational therapy in clinical studies, marking an important milestone in our journey to bring a new treatment option to patients who need better solutions.

We are proud of how far we have come.
And we know this is just the beginning.

Thank you to our team, (clinical) partners, investors, participating hospitals, and especially the patients who inspire us every day.

𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘣𝘦𝘪𝘯𝘨 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘦𝘥 𝘪𝘯 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘴𝘵𝘶𝘥𝘪𝘦𝘴. 𝘐𝘵 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦. 𝘕𝘰 𝘤𝘭𝘢𝘪𝘮𝘴 𝘢𝘳𝘦 𝘮𝘢𝘥𝘦 𝘳𝘦𝘨𝘢𝘳𝘥𝘪𝘯𝘨 𝘪𝘵𝘴 𝘴𝘢𝘧𝘦𝘵𝘺 𝘰𝘳 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘯𝘦𝘴𝘴.

02/03/2026

The American Migraine Foundation illustrates what it means to live with migraine.

Migraine is a debilitating neurological condition that often goes unseen. What is visible on the outside does not always reflect the internal experience, which can include brain fog, dizziness, nausea, fatigue, and sensitivity to light.

By making the invisible visible, the American Migraine Foundation contributes to greater awareness and understanding of the impact of migraine for the 40 million Americans living with the condition.

17/02/2026

From reactive headache care to real-time intervention.

Cluster headache is one of the most severe pain conditions, yet care still relies largely on retrospective reports and pain diaries. This limits timely intervention and delays effective treatment.

CLUSTERSENSE is an OPZuid-funded project (2025–2028) developing an AI-driven, closed-loop system that combines continuous physiological monitoring with personalized neurostimulation to detect and respond to attacks as they occur.

Within the project, Salvia BioElectronics contributes implantable neurostimulation technology, further developed toward adaptive, data-informed use, alongside Mentech Engineering and Leiden University Medical Center (LUMC).

By integrating AI, sensing, and clinical expertise, CLUSTERSENSE supports a more objective and data-driven approach to cluster headache care.

Read more about the project here: https://www.salviabioelectronics.com/news/clustersense-project

12/02/2026

Proud to stand with the migraine community.

At 𝐇𝐞𝐚𝐝𝐚𝐜𝐡𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐢𝐥𝐥 in Washington, DC this week, nearly 300 advocates are meeting with lawmakers to represent the 40 million Americans living with migraine and other headache disorders. Across 280 meetings, they’re sharing lived experiences and highlighting the need for improved access to care, stronger research, and meaningful support for patients.

We are proud of our colleague Roni Diaz (VP Clinical & Regulatory Affairs) for standing alongside patients and advocates at Headache on the Hill, helping ensure the patient voice remains central to these important conversations.

In the photo, Roni is pictured with Amaal Starling, MD, FAHS, FAAN, Headache Neurologist and Associate Professor of Neurology at Mayo Clinic, receiving the Heroism in Headache Advocacy Award — a recognition of leadership and dedication to the migraine community. Roni is also pictured with members of the Utah/New Mexico delegation and congressional staff, united in support of patient-centered solutions.

Key legislative discussions this week include:

➡️The HEADACHE Act – landmark legislation to strengthen federal research, improve data collection, and increase public awareness around headache disorders.
➡️The Safe Step Act – helping ensure patients can access the medications their physicians prescribe without unnecessary step-therapy delays.
➡️The CONNECT for Health Act – expanding and making permanent critical telehealth flexibilities to improve access to specialty care.

As a clinical-stage medtech company advancing neuromodulation therapies for migraine and cluster headache, we believe innovation and patient access go hand in hand.

We’re honored to stand with patients, clinicians, researchers, and advocates working toward a future where migraine is better understood, better treated, and never overlooked.

11/02/2026

Exciting news! 📢 As we advance the clinical development of our novel neuromodulation therapy for migraine, Daniel Balkcom joins Salvia as Vice President, U.S. Commercial Strategy and Operations.

Balkcom, a seasoned neuromodulation commercial leader, will lead and define the strategic direction of Salvia’s U.S. activities, shaping the company’s commercial strategy and approach to future market access and adoption of its proprietary MySalvia Therapy. He will also oversee commercial operations, working closely with the executive leadership team in Europe and the United States to translate clinical and regulatory progress into a focused strategy for U.S. market preparation.

“We are very pleased to welcome Daniel to Salvia,” said Hubert Martens, Founder and CEO. “His extensive experience in neuromodulation and in successfully bringing novel therapies to the U.S. market will be instrumental in shaping the future of MySalvia Therapy.”

“Salvia is taking a disciplined, evidence-driven approach to developing a new therapy for people living with migraine,” said Balkcom. “I’m excited to lead the development of the company’s U.S. commercial strategy and build the foundation that will support future market access and adoption.”

Read the full announcement here: https://www.salviabioelectronics.com/news/salvia-bioelectronics-appoints-daniel-balkcom-as-vice-president-u-s-commercial-strategy-and-operations

09/02/2026

We are proud that our colleague Roni Diaz (VP Clinical & Regulatory Affairs) is in Washington, DC for 𝐇𝐞𝐚𝐝𝐚𝐜𝐡𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐢𝐥𝐥, joining nearly 300 advocates from across the US to meet face-to-face with members of Congress and raise awareness for people living with migraine and other headache disorders.

They are meeting with members of Congress to share real-world experiences and highlight key areas that can help improve care for those affected.

Migraine and other headache disorders can have a substantial impact on daily life, yet they are often overlooked. By raising awareness and sharing personal perspectives, we can help improve access to care and enhance the quality of life for those living with these conditions.

𝘏𝘦𝘢𝘥𝘢𝘤𝘩𝘦 𝘰𝘯 𝘵𝘩𝘦 𝘏𝘪𝘭𝘭 𝘪𝘴 𝘢 𝘣𝘪-𝘢𝘯𝘯𝘶𝘢𝘭 𝘢𝘥𝘷𝘰𝘤𝘢𝘤𝘺 𝘦𝘷𝘦𝘯𝘵 𝘰𝘳𝘨𝘢𝘯𝘪𝘻𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘈𝘭𝘭𝘪𝘢𝘯𝘤𝘦 𝘧𝘰𝘳 𝘏𝘦𝘢𝘥𝘢𝘤𝘩𝘦 𝘋𝘪𝘴𝘰𝘳𝘥𝘦𝘳𝘴 𝘈𝘥𝘷𝘰𝘤𝘢𝘤𝘺. 𝘛𝘩𝘦 𝘦𝘷𝘦𝘯𝘵 𝘣𝘳𝘪𝘯𝘨𝘴 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴, 𝘤𝘢𝘳𝘦𝘨𝘪𝘷𝘦𝘳𝘴, 𝘤𝘭𝘪𝘯𝘪𝘤𝘪𝘢𝘯𝘴, 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩𝘦𝘳𝘴, 𝘢𝘯𝘥 𝘢𝘥𝘷𝘰𝘤𝘢𝘵𝘦𝘴 𝘧𝘳𝘰𝘮 𝘢𝘤𝘳𝘰𝘴𝘴 𝘵𝘩𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘺 𝘵𝘰 𝘦𝘥𝘶𝘤𝘢𝘵𝘦 𝘭𝘢𝘸𝘮𝘢𝘬𝘦𝘳𝘴 𝘢𝘣𝘰𝘶𝘵 𝘩𝘦𝘢𝘥𝘢𝘤𝘩𝘦 𝘥𝘪𝘴𝘰𝘳𝘥𝘦𝘳𝘴 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘶𝘳𝘨𝘦𝘯𝘵 𝘯𝘦𝘦𝘥 𝘧𝘰𝘳 𝘪𝘮𝘱𝘳𝘰𝘷𝘦𝘥 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘤𝘢𝘳𝘦, 𝘳𝘦𝘥𝘶𝘤𝘦𝘥 𝘪𝘯𝘴𝘶𝘳𝘢𝘯𝘤𝘦 𝘣𝘢𝘳𝘳𝘪𝘦𝘳𝘴, 𝘢𝘯𝘥 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘦𝘥 𝘧𝘦𝘥𝘦𝘳𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘶𝘯𝘥𝘪𝘯𝘨.

Salvia BioElectronics